Preview Mode Links will not work in preview mode

Jul 14, 2020

Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Interview with Dr Lheureux on the following topic:

  • Overall survival data with maintenance olaparib for platinum-sensitive recurrent OC with germline BRCA mutation from the Phase III SOLO-2 trial; optimal integration of PARP inhibitors in the treatment of recurrent disease (00:00)

CME information and select publications